Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyThu, 06 Jun 2024 11:42:04 +0200Fri, 05 Apr 2024 17:31:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0102/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000576-pip01-09-m14Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0102/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000576-pip01-09-m14Fri, 05 Apr 2024 17:31:00 +0200Human medicine